Here are the DEF 14A proxy statements from CRISPR Therapeutics AG (CRSP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CRSP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRSP filings page.
CRISPR Therapeutics AG is asking shareholders to vote at its 2026 annual general meeting on June 4, 2026 in Zurich. Items include approval of the 2025 Swiss management report and financial statements, carrying forward a total accumulated net loss of CHF 1,894,391,436 and granting discharge to the Board of Directors and Executive Committee.
Shareholders will vote on re-electing eleven directors, the compensation committee and the independent voting rights representative, as well as approving maximum 2026–2027 compensation and equity pools for the Board and Executive Committee. Additional proposals cover increasing the capital band, raising conditional share capital for convertible instruments and approving a new 2026 Stock Option and Incentive Plan that will use remaining shares from prior plans.